Published on
September 19, 2020
- 15:00 GMT
Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial Cancer
Trodelvy achieves a 27 percent overall response rate and a 5.9-month median duration of response in heavily-pretreated patients with metastatic urothelial cancer (mUC) sBLA submission for accelerated approval expected in fourth quarter 2020, pending FDA …
Distribution channels:
Culture, Society & Lifestyle, Media, Advertising & PR
...
